Figure 3.

Additional individual direct drug costs attributable to T2DM by treatment phase and resource category in 2010.*% calculated by treatment line; ex: additionnal drug costs in monotherapy = 28% antidiabetics, 51% cardiovascular system, 7% nervous system 7% blood and blood forming organs, 7% others.

Guelfucci et al. BMC Endocrine Disorders 2013 13:15   doi:10.1186/1472-6823-13-15
Download authors' original image